Device Trial Radar · NCT00707720
Multi-Center Feasibility Study of Trans-oral Endoscopic Restrictive Implant System (TERIS) for Treatment of Obesity
Last checked: Nov 21, 2026Latest source record: Apr 10, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- BaroSense Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Barosense Trans-oral Endoscopic Restrictive Implant System (TERIS) is an investigational system being evaluated for safety The system uses endoscopic guidance to trans-orally implant a restrictive reservoir for food entering the stomach in obese and morbidly obese subjects to induce early and prolonged satiety. The Intended Use of the system is for the treatment of obesity.
Conditions
- Obesity
Interventions
TERIS procedureDevice
The implantation of the restrictive implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events relating to the procedure and deviceTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hopital Laval
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.